Royalty Pharma plc(RPRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #171 of 2,961 stocksTOP 10%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
RPRX Stock Analysis & AI Quality Score
Data updated 2026-09-10AI stock analysis and institutional research for Royalty Pharma plc (RPRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RPRX at 71.8/100 on a 32-signal composite quality model, placing it at rank #171 of 2,961 stocks — the top 10% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Royalty Pharma plc reports quarterly revenue of $674.1M, net income of $17.9M. Top institutional holders of RPRX by reported 13-F value include MORGAN STANLEY, Capital International Investors, BlackRock, based on the most recent SEC filings. RPRX trades on the Nasdaq exchange and files with the SEC under CIK 1802768. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RPRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Royalty Pharma plc directly from SEC EDGAR. Royalty Pharma plc's 13F Pro composite quality score has ranged between 65 and 72 since 2026, currently 71.8 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$674.1M
Net Income
Q2 2026
$17.9M
ROIC
Q2 2026
2.8%
D/E Ratio
Q2 2026
0.95
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+5.1% YoYNet Income
-10.2% YoYOperating Income
+20.7% YoYEPS (Diluted)
-6.8% YoYTotal Assets
+7.7% YoYTotal Debt
+8.4% YoYOp. Cash Flow
-10.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.38B +5.1% | $2.26B -3.9% | $2.35B +5.2% | $2.24B -2.3% | $2.29B +7.9% | $2.12B |
| Net Income | $770.9M -10.2% | $859.0M -24.3% | $1.13B +2549.5% | $42.8M -93.1% | $619.7M -36.4% | $975.0M |
| Operating Income | $1.56B +20.7% | $1.29B -13.4% | $1.49B +385.9% | $307.1M -78.5% | $1.43B -10.3% | $1.60B |
| EPS (Diluted) | $1.78 -6.8% | $1.91 -24.5% | $2.53 +2430.0% | $0.10 -93.3% | $1.49 +12.9% | $1.32 |
| Total Assets | $19.62B +7.7% | $18.22B +11.2% | $16.38B -2.6% | $16.81B -4.0% | $17.52B +9.3% | $16.02B |
| Total Debt | $9.33B +8.4% | $8.61B +40.3% | $6.14B -24.4% | $8.11B +14.3% | $7.10B +22.0% | $5.82B |
| Operating Cash Flow | $2.49B -10.1% | $2.77B -7.3% | $2.99B +39.4% | $2.14B +6.3% | $2.02B -0.8% | $2.03B |
Get alerted when RPRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Royalty Pharma plc including:
Top Institutional Holders of RPRX
MORGAN STANLEY
$2.4B42,931,597 shCapital International Investors
$2.0B35,273,770 shBlackRock, Inc.
$1.6B27,832,977 shFMR LLC
$1.4B24,513,814 shSTATE STREET CORP
$691.8M12,338,229 shPRICE T ROWE ASSOCIATES INC /MD/
$627.6M11,193,657 shSwedbank AB
$601.4M10,726,608 shBAILLIE GIFFORD & CO
$561.6M10,015,578 shCapital World Investors
$533.6M9,517,337 shGEODE CAPITAL MANAGEMENT, LLC
$450.6M8,058,048 sh
| Fund | Value | Shares |
|---|---|---|
| MORGAN STANLEY | $2.4B | 42,931,597 |
| Capital International Investors | $2.0B | 35,273,770 |
| BlackRock, Inc. | $1.6B | 27,832,977 |
| FMR LLC | $1.4B | 24,513,814 |
| STATE STREET CORP | $691.8M | 12,338,229 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $627.6M | 11,193,657 |
| Swedbank AB | $601.4M | 10,726,608 |
| BAILLIE GIFFORD & CO | $561.6M | 10,015,578 |
| Capital World Investors | $533.6M | 9,517,337 |
| GEODE CAPITAL MANAGEMENT, LLC | $450.6M | 8,058,048 |
Companies Similar to RPRX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
REGENERON PHARMACEUTICALS, INC.
BIOGEN INC.
UNITED THERAPEUTICS Corp
VERTEX PHARMACEUTICALS INC / MA
Edwards Lifesciences Corp
ALNYLAM PHARMACEUTICALS, INC.
ALIGN TECHNOLOGY INC
INSULET CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put RPRX on your watchlist
Track score changes the day Royalty Pharma plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RPRX a good stock to buy?
13F Pro's AI-powered analysis of Royalty Pharma plc (RPRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RPRX are available on the RPRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RPRX is classified as a large company.
Which hedge funds own RPRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RPRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Royalty Pharma plc's investment landscape.